NCT03883022 Vancomycin Powder Combined With Autogenous Bone Graft as a Prevention for Post-operative Infection for Spine Surgery
| NCT ID | NCT03883022 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Taipei Veterans General Hospital, Taiwan |
| Condition | Spinal Fusion |
| Study Type | INTERVENTIONAL |
| Enrollment | 400 participants |
| Start Date | 2018-09-03 |
| Primary Completion | 2027-09-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 400 participants in total. It began in 2018-09-03 with a primary completion date of 2027-09-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Deep surgical site infection (DSSI) is one of the most challenging complications for spinal surgeons and can lead to a poor clinical outcome. This ambispective study was designed to examine the effect of vancomycin powder mixed with autogenous bone graft and bone substitute on preventing deep surgical site infection (DSSI) in degenerative lumbar fusion surgeries as well as any interference with bony fusion.
Eligibility Criteria
Inclusion Criteria: * Patients who have instrumented spine fusion surgery due to failed conservative treatment (bed rest, medication, rehabilitation programs) for 3 to 6 months * Patients who are willing to sign the surgical permit after the surgeon explains all surgical procedures along with the surgical risks * Patients who fully understand the surgical procedures as well as the surgical risks and are willing to sign the surgical permit and the inform consent * Patients who agree one more blood withdrawal after operation Exclusion Criteria: * Patients who agree to accept the spine surgery but do not agree to sign the inform consent * Patients who have allergic reaction to vancomycin
Contact & Investigator
Shih-Tien Wang, MD
STUDY CHAIR
Taipei Veterans General Hospital, Taiwan
Frequently Asked Questions
Who can join the NCT03883022 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, studying Spinal Fusion. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03883022 currently recruiting?
Yes, NCT03883022 is actively recruiting participants. Contact the research team at stwang@vghtpe.gov.tw for enrollment information.
Where is the NCT03883022 trial being conducted?
This trial is being conducted at Taipei, Taiwan.
Who is sponsoring the NCT03883022 clinical trial?
NCT03883022 is sponsored by Taipei Veterans General Hospital, Taiwan. The principal investigator is Shih-Tien Wang, MD at Taipei Veterans General Hospital, Taiwan. The trial plans to enroll 400 participants.